Search details
1.
Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
BMC Infect Dis
; 24(1): 413, 2024 Apr 19.
Article
in English
| MEDLINE | ID: mdl-38641791
2.
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Lancet Infect Dis
; 21(8): 1107-1119, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33773111
Results
1 -
2
de 2
1
Next >
>>